Pierre Fabre Group

Belkins
Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

Related News

PRACTICE MANAGEMENT

ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Farxiga | January 07, 2021

news image

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...

Read More

KYAN THERAPEUTICS EXCLUSIVELY LICENSES SMALL MOLECULE HDAC INHIBITORS FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics, Inc. | September 24, 2020

news image

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More

MOVILITAS.CLOUD™ VRS SOLUTION CLARIFIES DSCSA VERIFICATION FOR PHARMACEUTICAL WHOLESALE DISTRIBUTORS AND MANUFACTURERS

Movilitas | July 13, 2020

news image

Movilitas announced today the availability of its Movilitas.Cloud™ Verification Router Service (VRS) solution that simplifies the verification process and compliance for pharmaceutical wholesale distributors and manufacturers. The new mobile app provides an out-of-the-box solution for the November 2020 Drug Supply Chain Security Act (DSCSA) saleable returns verification deadline. With the upcoming regulation, wholesale distributors must verify the serialized product identifi...

Read More

WAREHOUSE OPTIMIZATION HELPED A PHARMA COMPANY TO INTEGRATE DATA FROM DISPARATE SOURCE WITHIN THE SUPPLY CHAIN

Businesswire | May 07, 2020

news image

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent engagement which examines the role of warehouse optimization in the pharma industry. This success story offers comprehensive insights into how Quantzig helped a pharma company who was facing a multitude of warehouse optimization and distribution challenges that were further complicated by the nature of the drugs that the...

Read More

PRACTICE MANAGEMENT

Farxiga | January 07, 2021

news image

ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...

Read More

KYAN Therapeutics, Inc. | September 24, 2020

news image

KYAN THERAPEUTICS EXCLUSIVELY LICENSES SMALL MOLECULE HDAC INHIBITORS FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More

Movilitas | July 13, 2020

news image

MOVILITAS.CLOUD™ VRS SOLUTION CLARIFIES DSCSA VERIFICATION FOR PHARMACEUTICAL WHOLESALE DISTRIBUTORS AND MANUFACTURERS

Movilitas announced today the availability of its Movilitas.Cloud™ Verification Router Service (VRS) solution that simplifies the verification process and compliance for pharmaceutical wholesale distributors and manufacturers. The new mobile app provides an out-of-the-box solution for the November 2020 Drug Supply Chain Security Act (DSCSA) saleable returns verification deadline. With the upcoming regulation, wholesale distributors must verify the serialized product identifi...

Read More

Businesswire | May 07, 2020

news image

WAREHOUSE OPTIMIZATION HELPED A PHARMA COMPANY TO INTEGRATE DATA FROM DISPARATE SOURCE WITHIN THE SUPPLY CHAIN

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent engagement which examines the role of warehouse optimization in the pharma industry. This success story offers comprehensive insights into how Quantzig helped a pharma company who was facing a multitude of warehouse optimization and distribution challenges that were further complicated by the nature of the drugs that the...

Read More